Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted

Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted

NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially...

Nota AI Has Two MoE Quantization Papers Accepted at ICML 2026 Workshop, Demonstrating Global Competitiveness in Large-Scale AI Optimization

Nota AI Has Two MoE Quantization Papers Accepted at ICML 2026 Workshop, Demonstrating Global Competitiveness in Large-Scale AI Optimization

Two papers on MoE-specific quantization algorithms accepted at a workshop held in conjunction with ICML 2026 Recognition follows Nota AI's overall win at the NVIDIA Nemotron Hackathon Strengthening core optimization technologies to make large-scale...

Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87

Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87

HANGZHOU, China, May 8, 2026 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that the Center...

TLX101-Px (Pixlumi®) MAA Accepted in Europe

TLX101-Px (Pixlumi®) MAA Accepted in Europe

MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px...

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today...

Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE

Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE

SUZHOU, China, March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate...

menu
menu